

Securities Code: 4581
June 28, 2018

Taisho Pharmaceutical Holdings Co., Ltd.
3-24-1, Takada, Toshima-ku, Tokyo
Akira Uehara
Chief Executive Officer (Representative)

To our shareholders

Notice of Resolution at the 7th Ordinary General Meeting of Shareholders

Taisho Pharmaceutical Holdings Co., Ltd. (the “Company”) hereby gives notice of the reports made and resolution passed at the 7th Ordinary General Meeting of Shareholders held today. The details are as follows.

Matters reported

1. Business Report, Consolidated Financial Statements and audit reports of Consolidated Financial Statements by Accounting Auditor and the Audit & Supervisory Board, for the 7th fiscal year (April 1, 2017 to March 31, 2018)
2. Non-consolidated Financial Statements for the 7th fiscal year (April 1, 2017 to March 31, 2018)

The contents of the above were reported.

Matter resolved

Proposal: Appropriation of surplus
This proposal was approved and adopted as proposed and the year-end dividend was set at 60 yen per share.

[Translation for Reference Purposes Only]

Payment of the Year-end Dividend

The year-end dividend for the 7th fiscal year will be paid by means of the enclosed “Year-end Dividend Warrant for the 7th Fiscal Year.” Please collect your dividend at a nearby head office, branch office or subbranch office of Japan Post Bank, or a post office (providing banking services) during the payment period (from June 29, 2018 to July 31, 2018).

For shareholders who have designated a dividend transfer account, please find enclosed the “Statement of Year-end Dividend for the 7th Fiscal Year” and “Notification of Confirmation of the Dividend Transfer Account.”

For shareholders who are to receive the dividend by means of the “Year-end Dividend Warrant for the 7th Fiscal Year,” please find enclosed the “Statement of Year-end Dividend for the 7th Fiscal Year,” which may be used as a confirmation document for the amount of the dividend received, or as supporting materials when you file an income tax return.